CD19 and cancer: In 2020, Priceman et al. reported that the use of anti-CD19 CAR-T cells in combination with OV19t (an OV that induces cancer cells to express a truncated non-signaling variant of CD19) resulted in a complete response in approximately 60% of mice as opposed to 22% of mice treated with OV19t alone [195].